The National Institute for Health and Care Excellence has been invited to consider the following topics for technology appraisal.

For each proposed appraisal, the table gives the suggested remit, the dates of the consultation on that remit, an e-mail address to send any enquiries to regarding the proposed appraisal, and links to any documents being consulted on in addition to the suggested remit.

Jump to:

 

 

SGT320 for treating persistent allergic rhinitis caused by house dust mites

Suggested remit

To appraise the clinical and cost effectiveness of SGT320 within its marketing authorisation for treating persistent allergic rhinitis caused by house dust mites.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

23 November 2017 – 21 December 2017

 
 

Batch

58

ID number

1278

Scoping workshop

Monday 15 January 2018 – London *

* On receiving updated regulatory timing information from the company that markets STG320, NICE has agreed that holding a scoping workshop at this time would not be appropriate. Consequently the scoping workshop arranged for the 15 January 2018 will be cancelled and the consultation on the draft scope will not continue. The workshop and consultation will be rescheduled to take place in line with anticipated regulatory approval timings. We apologise for any inconvenience this may cause.

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Documents

 

Back to top


Patiromer for treating hyperkalaemia

Suggested remit

To appraise the clinical and cost effectiveness of patiromer within its marketing authorisation for treating hyperkalaemia.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

21 November 2017 – 19 December 2017

 
 

Batch

58

ID number

877

Scoping workshop

Thursday 11 January 2018 – London (AM)

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Documents

 

Back to top

 

NBTXR-3 for treating soft tissue sarcoma

Suggested remit

To appraise the clinical and cost effectiveness of NBTXR-3 within its CE marked indication for neoadjuvant treatment of soft tissue sarcoma.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

21 November 2017 – 19 December 2017

 
 

Batch

58

ID number

1050

Scoping workshop

Thursday 11 January 2018 – London (PM) *

* After careful review of the consultation comments received NICE has agreed that a scoping workshop would not be appropriate. As a consequence of this the scoping workshop arranged for Thursday 11 January 2018 at 14:00.has been cancelled. We apologise for any inconvenience this may cause. NICE will still submit a report to the Department of Health summarising the results of the consultation. The report will help ministers to decide whether or not the technology should be formally referred to NICE for appraisal.

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Documents

 

Back to top

 

Cannabidiol for adjuvant treatment of seizures associated with Dravet syndrome or Lennox-Gastaut syndrome

Suggested remit

To appraise the clinical and cost effectiveness of cannabidiol within its marketing authorisation for adjuvant treatment of seizures associated with Dravet syndrome or Lennox-Gastaut syndrome.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

21 November 2017 – 19 December 2017

 
 

Batch

58

ID number

1211

Scoping workshop

Tuesday 16 January 2018 – London (AM)

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Documents

 

Back to top

 

Dupilumab for treating severe asthma

Suggested remit

To appraise the clinical and cost effectiveness of dupilumab within its marketing authorisation for treating severe asthma inadequately controlled with inhaled corticosteroids.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

22 November 2017 – 20 December 2017

 
 

Batch

58

ID number

1213

Scoping workshop

Tuesday 16 January 2018 – London (PM)

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Documents

 

Back to top

 

Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation

Suggested remit

To appraise the clinical and cost effectiveness of tezacaftor in combination with ivacaftor within its marketing authorisation for treating cystic fibrosis in people with the F508del mutation.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

23 November 2017 – 21 December 2017

 
 

Batch

58

ID number

1303

Scoping workshop

Consultation only

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Documents

 

Back to top

 

Drug-eluting beads loaded with doxorubicin for treating hepatocellular carcinoma

Suggested remit

To appraise the clinical and cost effectiveness of drug-eluting beads loaded with doxorubicin within their approved indications for treating hepatocellular carcinoma.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

9 January 2018 – 5 February 2018

 
 

Batch

58

ID number

999

Scoping workshop

Friday 2 March 2018 - Manchester

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Documents

 

Back to top

 

Drug-eluting beads loaded with irinotecan for treating liver metastases in colorectal cancer

Suggested remit

To appraise the clinical and cost effectiveness of drug-eluding beads loaded with irinotecan within its approved indication for use for treating liver metastases in colorectal cancer.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

9 January 2018 – 5 February 2018

 
 

Batch

58

ID number

1032

Scoping workshop

Friday 2 March 2018 - Manchester

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Documents

 

Back to top

 

TheraSphere for treating advanced hepatocellular carcinoma

Suggested remit

To appraise the clinical and cost effectiveness of TheraSphere within its approved indication for treating advanced hepatocellular carcinoma.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

9 January 2018 – 5 February 2018

 
 

Batch

58

ID number

1276

Scoping workshop

Friday 2 March 2018 - Manchester

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Documents

 

Back to top

 

Dapagliflozin and empagliflozin, in combination with insulin, for treating type 1 diabetes

Suggested remit

To appraise the clinical and cost effectiveness of dapagliflozin and empagliflozin within their marketing authorisation for treating type 1 diabetes.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

19 September 2017 – 17 October 2017

 
 

Batch

57

ID number

1217

Scoping workshop

Tuesday 7 November 2017 (PM) - London

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Documents

 

Back to top

 

Tofacitinib for treating active psoriatic arthritis following disease-modifying anti-rheumatic drugs

Suggested remit

To appraise the clinical and cost effectiveness of tofacitinib within its marketing authorisation for treating active psoriatic arthritis in adults whose disease has not responded adequately to previous disease-modifying anti-rheumatic drug (DMARD) therapy, or for whom DMARDs are not tolerated or contraindicated.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

19 September 2017 – 17 October 2017

 
 

Batch

57

ID number

1220

Scoping workshop

Consultation only

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Documents

 

Back to top

 

Tofacitinib for moderately to severely active ulcerative colitis

Suggested remit

To appraise the clinical and cost effectiveness of tofacitinib within its marketing authorisation for treating moderately to severely active ulcerative colitis.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

20 September 2017 – 18 October 2017

 
 

Batch

57

ID number

1218

Scoping workshop

Consultation only

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Documents

 

Back to top

 

Mepolizumab for treating chronic obstructive pulmonary disease

Suggested remit

To appraise the clinical and cost effectiveness of mepolizumab within its marketing authorisation for treating chronic obstructive pulmonary disease.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

20 September 2017 – 18 October 2017

 
 

Batch

57

ID number

1237

Scoping workshop

Consultation only

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Documents

 

Back to top

 

Certolizumab pegol for treating moderate to severe plaque psoriasis

Suggested remit

To appraise the clinical and cost effectiveness of certolizumab pegol within its marketing authorisation for treating moderate to severe plaque psoriasis.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

21 September 2017 – 19 October 2017

 
 

Batch

57

ID number

1232

Scoping workshop

Consultation only

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Documents

 

Back to top

 

Letermovir for preventing cytomegalovirus infection in sero-positive patients having allogeneic haematopoietic stem cell transplantation

Suggested remit

To appraise the clinical and cost effectiveness of letermovir within its marketing authorisation for preventing cytomegalovirus infection in sero-positive patients having allogeneic haematopoietic stem cell transplantation.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

14 July 2017 – 11 August 2017

 
 

Batch

56

ID number

1153

Scoping workshop

Consultation only

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Documents

 

Back to top

 

Lifitegrast for treating dry eye disease

Suggested remit

To appraise the clinical and cost effectiveness of lifitegrast within its marketing authorisation for treating dry eye disease.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

17 July 2017 – 14 August 2017

 
 

Batch

56

ID number

1229

Scoping workshop

Tuesday 5 September (AM) - London

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Documents

 

Back to top

 

Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations

Suggested remit

To appraise the clinical and cost effectiveness of voretigene neparvovec within its marketing authorisation for treating inherited retinal dystrophies caused by RPE65 gene mutations.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

19 July 2017 – 16 August 2017

 
 

Batch

56

ID number

1054

Scoping workshop

Wednesday 13 September (PM) - London

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Documents

 

Back to top

Inhaled alpha-1 antitrypsin for treating emphysema

Suggested remit

To appraise the clinical and cost effectiveness of inhaled alpha-1 antitrypsin within its marketing authorisation for treating emphysema.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

24 May 2017 – 22 June 2017

 

Batch

55

 

ID number

1200

 

Scoping workshop

The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of inhaled alpha-1 antitrypsin for treating emphysema ID1200 We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this proposed appraisal.

The company that develop Inhaled alpha-1 antitrypsin have advised NICE that they have withdrawn their marketing authorisation application for this product for this indication and plan to resubmit their application in few years after collecting additional data from a planned phase 3 study. In light of this information, the Institute will not be progressing with the scoping exercise. Consequently, the scoping workshop arranged for Friday 14 July 2017 has been cancelled.

If you have any comments or concerns please contact the project manager for this proposed appraisal Michelle Adhemar on 44 (0)20 7045 2239 or via email on michelle.adhemar@nice.org.uk.

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Consultation documents

 

Back to top

 

Exploratory work of bevacizumab in eye conditions

Background

In 2010 the Department of Health asked NICE to explore with stakeholders what value NICE can add in advising the NHS on the clinical and cost effectiveness of Avastin (bevacizumab) to treat wet age-related macular degeneration, the leading cause of blindness in the UK, and other conditions affecting the eye.

 

Consultation on briefing document and provisional list of stakeholders

02 June 2010 – 30 June 2010

 
 

Exploratory workshop

13 July 2010 in Manchester

 

Back to top